| |||||||||||||||||||
| This tri-allelic mouse model develops induced malignant melanomas following topical application of tamoxifen. | |||||||||||||||||||
- Description
- Disease & phenotype
- Genes & alleles
- Genotyping
- Health & care
- References
- Pricing & purchasing
- Terms of use
Description
Strain Information
Type Congenic; Mutant Strain; Targeted Mutation; Transgenic; Additional information on Genetically Engineered and Mutant Mice. Visit our online Nomenclature tutorial. Additional information on Congenic nomenclature. Mating System Species laboratory mouse Generation F?+F5 (30-NOV-12)
Generation DefinitionsDonating Investigator Marcus Bosenberg, Yale University Description
Mice that are hemizygous for the Tg(Tyr-cre/ERT2)13Bos transgene, heterozygous for the Braftm1Mmcm allele and homozygous for the floxed Ptentm1Hwu allele are viable and fertile, but 25% will develop melanomas with an onset of 2 to 12 months of age. Topical application of tamoxifen results in development of pigmented skin lesions within 21-28 days, and which progress to malignant melanoma. Metastases are detected in lymph nodes and lung. All treated mutant mice developed metastases in regional draining lymph nodes.The Donating Investigator reports that by 6 months of age, mice hemizygous for the Tg(Tyr-cre/ERT2)13Bos transgene, heterozygous for the Braftm1Mmcm allele and homozygous for the floxed Ptentm1Hwu allele, exhibit a 25-60% spontaneous melanoma rate in the absence of 4-hydroxytamoxifen induction, due to "leaky" Cre recombinase expression and activity in a genetic background setting that is conducive to tumor formation.
Mice that are hemizygous for the Tg(Tyr-cre/ERT2)13Bos transgene, homozygous for the Braftm1Mmcm allele and homozygous for the floxed Ptentm1Hwu allele develop larger melanoma lesions with tamoxifen application.
Development
The Tyr::CreERT2 transgene was designed with the mouse tyrosinase promoter/enhancer regions upstream of a tamoxifen/4-hydroxytamoxifen-inducible CreERT2 fusion gene (Cre recombinase fused to a G400V/M543A/L544A triple mutation of the human estrogen receptor ligand binding domain). This transgene was microinjected into FVB/NJ fertilized oocytes. Mice from founder line 13 were found to have melanocyte specific cre activity and were backcrossed to C57BL/6J mice for at least 11 generations. Subsequently, the congenic strain was crossed to B6.129S4-Ptentm1Hwu and maintained as a double homozygote colony. The mice were then crossed to B6.129P2-Braftm1Mmcm mice to generate these triple mutant mice.
Control Information
| Control | ||
|---|---|---|
| 000664 C57BL/6J | ||
| Considerations for Choosing Controls | ||
Related Strains
Strains carrying Braftm1Mmcm allele
017837 B6.129P2(Cg)-Braftm1Mmcm/J View Strains carrying Braftm1Mmcm (1 strain)
006440 B6.129S4-Ptentm1Hwu/J 004597 C;129S4-Ptentm1Hwu/J
012328 B6.Cg-Tg(Tyr-cre/ERT2)13Bos/J
006373 129-Braftm1Sva/J
Additional Web Information
Introduction to Cre-lox technology
Phenotype
Phenotype Information
- Potential model based on gene homology relationships. Phenotypic similarity to the human disease has not been tested. Bannayan-Riley-Ruvalcaba Syndrome; BRRS (PTEN)
Cardiofaciocutaneous Syndrome (BRAF)
Cowden Syndrome 1; CWS1 (PTEN)
Endometrial Cancer (PTEN)
Glioma Susceptibility 2; GLM2 (PTEN)
Leopard Syndrome 3 (BRAF)
Lung Cancer (BRAF)
Macrocephaly/Autism Syndrome (PTEN)
Melanoma, Cutaneous Malignant, Susceptibility to, 1; CMM1 (PTEN)
Meningioma, Familial, Susceptibility to (PTEN)
Noonan Syndrome 7; NS7 (BRAF)
Phosphatase and Tensin Homolog; PTEN (PTEN)
Prostate Cancer (PTEN)
Squamous Cell Carcinoma, Head and Neck; HNSCC (PTEN)
Thyroid Carcinoma, Follicular; FTC (PTEN)
Vacterl Association with Hydrocephalus (PTEN)
This mouse can be used to support research in many areas including:
cre relatedCancer Research
Increased Tumor Incidence
Skin Cancers
Skin Cancers: Induced
Other
tumor metastasis
Research Tools
Cre-lox System
loxP-flanked Sequences
Cre Recombinase Expression: Inducible
Ptentm1Hwu relatedResearch Tools
Cre-lox System
Genetics Research
Mutagenesis and Transgenesis
Mutagenesis and Transgenesis: Cre-lox System
Cancer Research
Tumor Suppressor Genes
Cell Biology Research
Cell Cycle Regulation
Genes & Alleles
Gene & Allele Information provided by MGI
| Allele Symbol | Braftm1Mmcm | ||
|---|---|---|---|
| Allele Name | targeted mutation 1, Martin McMahon | ||
| Allele Type | Targeted (knock-in) | ||
| Common Name(s) | BRAFF-V600E; BrafCA; | ||
| Mutation Made By | Martin McMahon, University of California, San Francisco | ||
| Strain of Origin | 129P2/OlaHsd | ||
| Site of Expression | intranasal instillation of an adenovirus expressing Cre recombinase results in benign lung tumors that only rarely progress to adenocarcinoma. | ||
| Expressed Gene | BRAF, v-raf murine sarcoma viral oncogene homolog B1, human | ||
| Molecular Note |
A targeting vector was designed to insert a loxP site and the human BRAF cDNA covering exons 15-18 into intron 14, along with a floxed neo cassette. A modified exon 15 was engineered into the vector to encode Braf | ||
| Gene Symbol and Name | Braf, Braf transforming gene | ||
| Chromosome | 6 | ||
| Gene Common Name(s) | 9930012E13Rik; AA120551; AA387315; AA473386; B-RAF1; BRAF1; Braf transforming gene 2; Braf-2; Braf2; C87398; D6Ertd631e; DNA segment, Chr 6, ERATO Doi 631, expressed; NS7; RAFB1; RIKEN cDNA 9930012E13 gene; expressed sequence AA120551; expressed sequence AA387315; expressed sequence AA473386; expressed sequence C87398; | ||
| Allele Symbol | Ptentm1Hwu | ||
| Allele Name | targeted mutation 1, Hong Wu | ||
| Allele Type | Targeted (Floxed/Frt) | ||
| Common Name(s) | PTENF; Ptenex5lox; Ptenfl; Ptenflox; Ptenfx; Ptenlox; Ptenloxp; | ||
| Mutation Made By | Hong Wu, UCLA | ||
| Strain of Origin | 129S4/SvJae | ||
| ES Cell Line Name | LW1 | ||
| ES Cell Line Strain | 129S4/SvJae | ||
| Gene Symbol and Name | Pten, phosphatase and tensin homolog | ||
| Chromosome | 19 | ||
| Gene Common Name(s) | 10q23del; 2310035O07Rik; A130070J02Rik; AI463227; B430203M17Rik; BZS; CWS1; DEC; GLM2; MHAM; MMAC1; PTEN1; RIKEN cDNA 2310035O07 gene; RIKEN cDNA A130070J02 gene; RIKEN cDNA B430203M17 gene; TEP1; expressed sequence AI463227; | ||
| General Note |
Phenotypic Similarity to Human Syndrome: Chronic intestinal pseudoobstruction J:155110. Phenotypic Similarity to Human Syndrome: Granulosa cell tumor of the testis (GCTT) J:149060. Phenotypic Similarity to Human Syndrome: Granulosa cell tumor (GCT) J:142150. Phenotypic Similarity to Human Syndrome: Glioblastoma J:172585. Phenotypic Similarity to Human Syndrome: B cell lymphoma J:166155. Phenotypic Similarity to Human Syndrome: Astrocytoma J:134611 Phenotypic Similarity to Human Syndrome: Thyroid Carcinoma (J:177181) Phenotypic Similarity to Human Syndrome: Granulosa cell tumor (GCT) J:186144 Phenotypic Similarity to Human Syndrome: Granulosa cell tumor of the testis (GCTT) J:186144 | ||
| Molecular Note | A loxP flanked hygromycin resistance cassette was inserted 5' to exon 5, and a single loxP site was inserted 3' to exon 5, which encodes the phosphatase domain. The hygromycin cassette was removed in ES cells by transient Cre recombinase expression prior to the production of chimeric mice, leaving a single loxP site in place of the cassette. These insertions do not appear to have any effect on the normal function of the gene. [MGI Ref ID J:75117] | ||
| Allele Symbol | Tg(Tyr-cre/ERT2)13Bos | ||
| Allele Name | transgene insertion 13, Marcus Bosenberg | ||
| Allele Type | Transgenic (Cre/Flp) | ||
| Common Name(s) | Tyr::CreER; Tyr::CreERT2; | ||
| Mutation Made By | Marcus Bosenberg, Yale University | ||
| Strain of Origin | FVB | ||
| Site of Expression | tamoxifen-induced Cre activity is expressed in cutaneous melanocytes. | ||
| Expressed Gene | cre, cre recombinase, bacteriophage P1 | ||
| Cre recombinase is an enzyme derived from the bacteriophage P1 that specifically recognizes loxP sites. Cre has been shown to effectively mediate the excision of DNA located between loxP sites. After the excision event, the DNA ends recombine leaving a single loxP site in place of the intervening sequence. | |||
| Promoter | Tyr, tyrosinase, mouse, laboratory | ||
| Driver Note | Tyr | ||
| Inducible Note | induced by tamoxifen | ||
| Molecular Note | This transgene consists of a 5.5 kb fragment of the Tyr promoter and a 3.6 kb fragment of the Tyr enhancer driving expression of a tamoxifen inducible form of cre recombinase. 3 lines were generated which all showed tamoxifen-inducible Cre activity in cutaneous melanocytes. This is a representative record for all 3 lines. [MGI Ref ID J:110143] | ||
| Gene Symbol and Name | Tg(Tyr-cre/ERT2)13Bos, transgene insertion 13, Marcus Bosenberg | ||
| Chromosome | UN | ||
| Gene Common Name(s) | Tg(Tyr-cre/ERT2)1Bos; Tyr::CreERT2; transgene insertion 1, Marcus Bosenberg; | ||
Genotyping
Genotyping Information
Genotyping Protocols
Braftm1Mmcm, Melt Curve Analysis
Braftm1Mmcm, Standard PCR
Generic Cre Melt Curve Analysis, Melt Curve Analysis
Generic Cre, Standard PCR
Ptentm1Hwu, Standard PCR
Helpful Links
Genotyping resources and troubleshooting
References
References provided by MGI
Selected Reference(s)
Dankort D; Curley DP; Cartlidge RA; Nelson B; Karnezis AN; Damsky WE Jr; You MJ; DePinho RA; McMahon M; Bosenberg M. 2009. Braf(V600E) cooperates with Pten loss to induce metastatic melanoma. Nat Genet 41(5):544-52. [PubMed: 19282848] [MGI Ref ID J:151023]
Additional References
Braftm1Mmcm relatedPtentm1Hwu relatedBurd CE; Sorrentino JA; Clark KS; Darr DB; Krishnamurthy J; Deal AM; Bardeesy N; Castrillon DH; Beach DH; Sharpless NE. 2013. Monitoring tumorigenesis and senescence in vivo with a p16(INK4a)-luciferase model. Cell 152(1-2):340-51. [PubMed: 23332765] [MGI Ref ID J:193498]
Charles RP; Iezza G; Amendola E; Dankort D; McMahon M. 2011. Mutationally Activated BRAFV600E Elicits Papillary Thyroid Cancer in the Adult Mouse. Cancer Res 71(11):3863-71. [PubMed: 21512141] [MGI Ref ID J:172205]
Collisson EA; Trejo CL; Silva JM; Gu S; Korkola JE; Heiser LM; Charles RP; Rabinovich BA; Hann B; Dankort D; Spellman PT; Phillips WA; Gray JW; McMahon M. 2012. A central role for RAF-->MEK-->ERK signaling in the genesis of pancreatic ductal adenocarcinoma. Cancer Discov 2(8):685-93. [PubMed: 22628411] [MGI Ref ID J:193065]
Damsky WE; Curley DP; Santhanakrishnan M; Rosenbaum LE; Platt JT; Gould Rothberg BE; Taketo MM; Dankort D; Rimm DL; McMahon M; Bosenberg M. 2011. beta-Catenin Signaling Controls Metastasis in Braf-Activated Pten-Deficient Melanomas. Cancer Cell 20(6):741-54. [PubMed: 22172720] [MGI Ref ID J:178598]
Dankort D; Filenova E; Collado M; Serrano M; Jones K; McMahon M. 2007. A new mouse model to explore the initiation, progression, and therapy of BRAFV600E-induced lung tumors. Genes Dev 21(4):379-84. [PubMed: 17299132] [MGI Ref ID J:121715]
Held MA; Curley DP; Dankort D; McMahon M; Muthusamy V; Bosenberg MW. 2010. Characterization of melanoma cells capable of propagating tumors from a single cell. Cancer Res 70(1):388-97. [PubMed: 20048081] [MGI Ref ID J:155731]
Hooijkaas AI; Gadiot J; van der Valk M; Mooi WJ; Blank CU. 2012. Targeting BRAFV600E in an inducible murine model of melanoma. Am J Pathol 181(3):785-94. [PubMed: 22796458] [MGI Ref ID J:188523]
Huillard E; Hashizume R; Phillips JJ; Griveau A; Ihrie RA; Aoki Y; Nicolaides T; Perry A; Waldman T; McMahon M; Weiss WA; Petritsch C; James CD; Rowitch DH. 2012. Cooperative interactions of BRAFV600E kinase and CDKN2A locus deficiency in pediatric malignant astrocytoma as a basis for rational therapy. Proc Natl Acad Sci U S A 109(22):8710-5. [PubMed: 22586120] [MGI Ref ID J:184756]
Landrette SF; Cornett JC; Ni TK; Bosenberg MW; Xu T. 2011. piggyBac transposon somatic mutagenesis with an activated reporter and tracker (PB-SMART) for genetic screens in mice. PLoS One 6(10):e26650. [PubMed: 22039523] [MGI Ref ID J:179725]
Mitra D; Luo X; Morgan A; Wang J; Hoang MP; Lo J; Guerrero CR; Lennerz JK; Mihm MC; Wargo JA; Robinson KC; Devi SP; Vanover JC; D'Orazio JA; McMahon M; Bosenberg MW; Haigis KM; Haber DA; Wang Y; Fisher DE. 2012. An ultraviolet-radiation-independent pathway to melanoma carcinogenesis in the red hair/fair skin background. Nature 491(7424):449-53. [PubMed: 23123854] [MGI Ref ID J:189208]
Niault TS; Baccarini M. 2010. Targets of Raf in tumorigenesis. Carcinogenesis 31(7):1165-74. [PubMed: 20047953] [MGI Ref ID J:161650]
Tang N; Marshall WF; McMahon M; Metzger RJ; Martin GR. 2011. Control of mitotic spindle angle by the RAS-regulated ERK1/2 pathway determines lung tube shape. Science 333(6040):342-5. [PubMed: 21764747] [MGI Ref ID J:174194]
Tien AC; Tsai HH; Molofsky AV; McMahon M; Foo LC; Kaul A; Dougherty JD; Heintz N; Gutmann DH; Barres BA; Rowitch DH. 2012. Regulated temporal-spatial astrocyte precursor cell proliferation involves BRAF signalling in mammalian spinal cord. Development 139(14):2477-87. [PubMed: 22675209] [MGI Ref ID J:185602]
Trejo CL; Juan J; Vicent S; Sweet-Cordero A; McMahon M. 2012. MEK1/2 inhibition elicits regression of autochthonous lung tumors induced by KRASG12D or BRAFV600E. Cancer Res 72(12):3048-59. [PubMed: 22511580] [MGI Ref ID J:189336]
Wang J; Kobayashi T; Floc'h N; Kinkade CW; Aytes A; Dankort D; Lefebvre C; Mitrofanova A; Cardiff RD; McMahon M; Califano A; Shen MM; Abate-Shen C. 2012. B-Raf activation cooperates with PTEN loss to drive c-Myc expression in advanced prostate cancer. Cancer Res 72(18):4765-76. [PubMed: 22836754] [MGI Ref ID J:191327]
Tg(Tyr-cre/ERT2)13Bos relatedAdhikari D; Zheng W; Shen Y; Gorre N; Hamalainen T; Cooney AJ; Huhtaniemi I; Lan ZJ; Liu K. 2009. Tsc/mTORC1 signaling in oocytes governs the quiescence and activation of primordial follicles. Hum Mol Genet :. [PubMed: 19843540] [MGI Ref ID J:155357]
Ahmad I; Morton JP; Singh LB; Radulescu SM; Ridgway RA; Patel S; Woodgett J; Winton DJ; Taketo MM; Wu XR; Leung HY; Sansom OJ. 2010. beta-Catenin activation synergizes with PTEN loss to cause bladder cancer formation. Oncogene :. [PubMed: 20818428] [MGI Ref ID J:164579]
Ahmad I; Patel R; Singh LB; Nixon C; Seywright M; Barnetson RJ; Brunton VG; Muller WJ; Edwards J; Sansom OJ; Leung HY. 2011. HER2 overcomes PTEN (loss)-induced senescence to cause aggressive prostate cancer. Proc Natl Acad Sci U S A 108(39):16392-7. [PubMed: 21930937] [MGI Ref ID J:177138]
Ahmad I; Singh LB; Foth M; Morris CA; Taketo MM; Wu XR; Leung HY; Sansom OJ; Iwata T. 2011. K-Ras and {beta}-catenin mutations cooperate with Fgfr3 mutations in mice to promote tumorigenesis in the skin and lung, but not in the bladder. Dis Model Mech 4(4):548-55. [PubMed: 21504907] [MGI Ref ID J:174242]
Akins EJ; Moore ML; Tang S; Willingham MC; Tooze JA; Dubey P. 2010. In situ vaccination combined with androgen ablation and regulatory T-cell depletion reduces castration-resistant tumor burden in prostate-specific pten knockout mice. Cancer Res 70(9):3473-82. [PubMed: 20406970] [MGI Ref ID J:159457]
Alcantara Llaguno S; Chen J; Kwon CH; Jackson EL; Li Y; Burns DK; Alvarez-Buylla A; Parada LF. 2009. Malignant astrocytomas originate from neural stem/progenitor cells in a somatic tumor suppressor mouse model. Cancer Cell 15(1):45-56. [PubMed: 19111880] [MGI Ref ID J:143505]
Anzelon AN; Wu H; Rickert RC. 2003. Pten inactivation alters peripheral B lymphocyte fate and reconstitutes CD19 function. Nat Immunol 4(3):287-94. [PubMed: 12563260] [MGI Ref ID J:83213]
Berquin IM; Min Y; Wu R; Wu H; Chen YQ. 2005. Expression signature of the mouse prostate. J Biol Chem 280(43):36442-51. [PubMed: 16055444] [MGI Ref ID J:106938]
Berquin IM; Min Y; Wu R; Wu J; Perry D; Cline JM; Thomas MJ; Thornburg T; Kulik G; Smith A; Edwards IJ; D'Agostino R; Zhang H; Wu H; Kang JX; Chen YQ. 2007. Modulation of prostate cancer genetic risk by omega-3 and omega-6 fatty acids. J Clin Invest 117(7):1866-75. [PubMed: 17607361] [MGI Ref ID J:124208]
Bian Y; Hall B; Sun ZJ; Molinolo A; Chen W; Gutkind JS; Waes CV; Kulkarni AB. 2012. Loss of TGF-beta signaling and PTEN promotes head and neck squamous cell carcinoma through cellular senescence evasion and cancer-related inflammation. Oncogene 31(28):3322-32. [PubMed: 22037217] [MGI Ref ID J:194578]
Bonaguidi MA; Wheeler MA; Shapiro JS; Stadel RP; Sun GJ; Ming GL; Song H. 2011. In vivo clonal analysis reveals self-renewing and multipotent adult neural stem cell characteristics. Cell 145(7):1142-55. [PubMed: 21664664] [MGI Ref ID J:173371]
Boyer A; Paquet M; Lague MN; Hermo L; Boerboom D. 2009. Dysregulation of WNT/CTNNB1 and PI3K/AKT signaling in testicular stromal cells causes granulosa cell tumor of the testis. Carcinogenesis 30(5):869-78. [PubMed: 19237610] [MGI Ref ID J:149060]
Browne CD; Del Nagro CJ; Cato MH; Dengler HS; Rickert RC. 2009. Suppression of phosphatidylinositol 3,4,5-trisphosphate production is a key determinant of B cell anergy. Immunity 31(5):749-60. [PubMed: 19896393] [MGI Ref ID J:155314]
Bun Chan C; Liu X; Pradoldej S; Hao C; An J; Yepes M; Luo HR; Ye K. 2011. Phosphoinositide 3-kinase enhancer regulates neuronal dendritogenesis and survival in neocortex. J Neurosci 31(22):8083-92. [PubMed: 21632930] [MGI Ref ID J:173380]
Burd CE; Sorrentino JA; Clark KS; Darr DB; Krishnamurthy J; Deal AM; Bardeesy N; Castrillon DH; Beach DH; Sharpless NE. 2013. Monitoring tumorigenesis and senescence in vivo with a p16(INK4a)-luciferase model. Cell 152(1-2):340-51. [PubMed: 23332765] [MGI Ref ID J:193498]
Byun DS; Ahmed N; Nasser S; Shin J; Al-Obaidi S; Goel S; Corner GA; Wilson AJ; Flanagan DJ; Williams DS; Augenlicht LH; Vincan E; Mariadason JM. 2011. Intestinal epithelial-specific PTEN inactivation results in tumor formation. Am J Physiol Gastrointest Liver Physiol 301(5):G856-64. [PubMed: 21836055] [MGI Ref ID J:178019]
Cai Z; Simons DL; Fu XY; Feng GS; Wu SM; Zhang X. 2011. Loss of shp2-mediated mitogen-activated protein kinase signaling in muller glial cells results in retinal degeneration. Mol Cell Biol 31(14):2973-83. [PubMed: 21576358] [MGI Ref ID J:174095]
Chen CC; Stairs DB; Boxer RB; Belka GK; Horseman ND; Alvarez JV; Chodosh LA. 2012. Autocrine prolactin induced by the Pten-Akt pathway is required for lactation initiation and provides a direct link between the Akt and Stat5 pathways. Genes Dev 26(19):2154-68. [PubMed: 23028142] [MGI Ref ID J:188260]
Chen J; Li Y; Yu TS; McKay RM; Burns DK; Kernie SG; Parada LF. 2012. A restricted cell population propagates glioblastoma growth after chemotherapy. Nature 488(7412):522-6. [PubMed: 22854781] [MGI Ref ID J:186769]
Chen L; Park SM; Tumanov AV; Hau A; Sawada K; Feig C; Turner JR; Fu YX; Romero IL; Lengyel E; Peter ME. 2010. CD95 promotes tumour growth. Nature 465(7297):492-6. [PubMed: 20505730] [MGI Ref ID J:161953]
Chiao PJ; Ling J. 2011. Kras, Pten, NF-kappaB, and inflammation: dangerous liaisons. Cancer Discov 1(2):103-5. [PubMed: 22586351] [MGI Ref ID J:193072]
Choi N; Zhang B; Zhang L; Ittmann M; Xin L. 2012. Adult Murine Prostate Basal and Luminal Cells Are Self-Sustained Lineages that Can Both Serve as Targets for Prostate Cancer Initiation. Cancer Cell 21(2):253-65. [PubMed: 22340597] [MGI Ref ID J:181459]
Chow DK; Groszer M; Pribadi M; Machniki M; Carmichael ST; Liu X; Trachtenberg JT. 2009. Laminar and compartmental regulation of dendritic growth in mature cortex. Nat Neurosci 12(2):116-8. [PubMed: 19151711] [MGI Ref ID J:145970]
Colombo S; Champeval D; Rambow F; Larue L. 2012. Transcriptomic analysis of mouse embryonic skin cells reveals previously unreported genes expressed in melanoblasts. J Invest Dermatol 132(1):170-8. [PubMed: 21850021] [MGI Ref ID J:180641]
Conley-LaComb MK; Huang W; Wang S; Shi D; Jung YS; Najy A; Fridman R; Bonfil RD; Cher ML; Chen YQ; Kim HR. 2012. PTEN regulates PDGF ligand switch for beta-PDGFR signaling in prostate cancer. Am J Pathol 180(3):1017-27. [PubMed: 22209699] [MGI Ref ID J:181962]
Costa PM; Cardoso AL; Pereira de Almeida LF; Bruce JN; Canoll P; Pedroso de Lima MC. 2012. PDGF-B-mediated downregulation of miR-21: new insights into PDGF signaling in glioblastoma. Hum Mol Genet 21(23):5118-30. [PubMed: 22922228] [MGI Ref ID J:188925]
Couto SS; Cao M; Duarte PC; Banach-Petrosky W; Wang S; Romanienko P; Wu H; Cardiff RD; Abate-Shen C; Cunha GR. 2009. Simultaneous haploinsufficiency of Pten and Trp53 tumor suppressor genes accelerates tumorigenesis in a mouse model of prostate cancer. Differentiation 77(1):103-11. [PubMed: 19281769] [MGI Ref ID J:147066]
Daikoku T; Hirota Y; Tranguch S; Joshi AR; DeMayo FJ; Lydon JP; Ellenson LH; Dey SK. 2008. Conditional loss of uterine Pten unfailingly and rapidly induces endometrial cancer in mice. Cancer Res 68(14):5619-27. [PubMed: 18632614] [MGI Ref ID J:139053]
Daikoku T; Tranguch S; Trofimova IN; Dinulescu DM; Jacks T; Nikitin AY; Connolly DC; Dey SK. 2006. Cyclooxygenase-1 is overexpressed in multiple genetically engineered mouse models of epithelial ovarian cancer. Cancer Res 66(5):2527-31. [PubMed: 16510568] [MGI Ref ID J:106703]
Dave V; Wert SE; Tanner T; Thitoff AR; Loudy DE; Whitsett JA. 2008. Conditional deletion of Pten causes bronchiolar hyperplasia. Am J Respir Cell Mol Biol 38(3):337-45. [PubMed: 17921358] [MGI Ref ID J:146355]
Diallo-Krou E; Yu J; Colby LA; Inoki K; Wilkinson JE; Thomas DG; Giordano TJ; Koenig RJ. 2009. Paired box gene 8-peroxisome proliferator-activated receptor-gamma fusion protein and loss of phosphatase and tensin homolog synergistically cause thyroid hyperplasia in transgenic mice. Endocrinology 150(11):5181-90. [PubMed: 19797117] [MGI Ref ID J:158236]
Diaz-Ruiz O; Zapata A; Shan L; Zhang Y; Tomac AC; Malik N; de la Cruz F; Backman CM. 2009. Selective deletion of PTEN in dopamine neurons leads to trophic effects and adaptation of striatal medium spiny projecting neurons. PLoS One 4(9):e7027. [PubMed: 19750226] [MGI Ref ID J:153622]
Dinulescu DM; Ince TA; Quade BJ; Shafer SA; Crowley D; Jacks T. 2005. Role of K-ras and Pten in the development of mouse models of endometriosis and endometrioid ovarian cancer. Nat Med 11(1):63-70. [PubMed: 15619626] [MGI Ref ID J:96296]
Dobson ME; Diallo-Krou E; Grachtchouk V; Yu J; Colby LA; Wilkinson JE; Giordano TJ; Koenig RJ. 2011. Pioglitazone Induces a Proadipogenic Antitumor Response in Mice with PAX8-PPAR{gamma} Fusion Protein Thyroid Carcinoma. Endocrinology 152(11):4455-65. [PubMed: 21952241] [MGI Ref ID J:177181]
Dourdin N; Schade B; Lesurf R; Hallett M; Munn RJ; Cardiff RD; Muller WJ. 2008. Phosphatase and tensin homologue deleted on chromosome 10 deficiency accelerates tumor induction in a mouse model of ErbB-2 mammary tumorigenesis. Cancer Res 68(7):2122-31. [PubMed: 18381417] [MGI Ref ID J:133305]
Duy C; Hurtz C; Shojaee S; Cerchietti L; Geng H; Swaminathan S; Klemm L; Kweon SM; Nahar R; Braig M; Park E; Kim YM; Hofmann WK; Herzog S; Jumaa H; Koeffler HP; Yu JJ; Heisterkamp N; Graeber TG; Wu H; Ye BH; Melnick A; Muschen M. 2011. BCL6 enables Ph+ acute lymphoblastic leukaemia cells to survive BCR-ABL1 kinase inhibition. Nature 473(7347):384-8. [PubMed: 21593872] [MGI Ref ID J:172636]
Ellwood-Yen K; Keilhack H; Kunii K; Dolinski B; Connor Y; Hu K; Nagashima K; O'Hare E; Erkul Y; Di Bacco A; Gargano D; Shomer NH; Angagaw M; Leccese E; Andrade P; Hurd M; Shin MK; Vogt TF; Northrup A; Bobkova EV; Kasibhatla S; Bronson RT; Scott ML; Draetta G; Richon V; Kohl N; Blume-Jensen P; Andersen JN; Kraus M. 2011. PDK1 Attenuation Fails to Prevent Tumor Formation in PTEN-Deficient Transgenic Mouse Models. Cancer Res 71(8):3052-65. [PubMed: 21493594] [MGI Ref ID J:170965]
Fan HY; Liu Z; Cahill N; Richards JS. 2008. Targeted disruption of pten in ovarian granulosa cells enhances ovulation and extends the life span of luteal cells. Mol Endocrinol 22(9):2128-40. [PubMed: 18606860] [MGI Ref ID J:138315]
Fenton TR; Nathanson D; Ponte de Albuquerque C; Kuga D; Iwanami A; Dang J; Yang H; Tanaka K; Oba-Shinjo SM; Uno M; del Mar Inda M; Wykosky J; Bachoo RM; James CD; DePinho RA; Vandenberg SR; Zhou H; Marie SK; Mischel PS; Cavenee WK; Furnari FB. 2012. Resistance to EGF receptor inhibitors in glioblastoma mediated by phosphorylation of the PTEN tumor suppressor at tyrosine 240. Proc Natl Acad Sci U S A 109(35):14164-9. [PubMed: 22891331] [MGI Ref ID J:188576]
Floc'h N; Kinkade CW; Kobayashi T; Aytes A; Lefebvre C; Mitrofanova A; Cardiff RD; Califano A; Shen MM; Abate-Shen C. 2012. Dual targeting of the Akt/mTOR signaling pathway inhibits castration-resistant prostate cancer in a genetically engineered mouse model. Cancer Res 72(17):4483-93. [PubMed: 22815528] [MGI Ref ID J:191334]
Freeman D; Lesche R; Kertesz N; Wang S; Li G; Gao J; Groszer M; Martinez-Diaz H; Rozengurt N; Thomas G; Liu X; Wu H. 2006. Genetic background controls tumor development in PTEN-deficient mice. Cancer Res 66(13):6492-6. [PubMed: 16818619] [MGI Ref ID J:110567]
Frew IJ; Minola A; Georgiev S; Hitz M; Moch H; Richard S; Vortmeyer AO; Krek W. 2008. Combined VHLH and PTEN mutation causes genital tract cystadenoma and squamous metaplasia. Mol Cell Biol 28(14):4536-48. [PubMed: 18474617] [MGI Ref ID J:137442]
Frew IJ; Thoma CR; Georgiev S; Minola A; Hitz M; Montani M; Moch H; Krek W. 2008. pVHL and PTEN tumour suppressor proteins cooperatively suppress kidney cyst formation. EMBO J 27(12):1747-57. [PubMed: 18497742] [MGI Ref ID J:137073]
Fu Y; Wey S; Wang M; Ye R; Liao CP; Roy-Burman P; Lee AS. 2008. Pten null prostate tumorigenesis and AKT activation are blocked by targeted knockout of ER chaperone GRP78/BiP in prostate epithelium. Proc Natl Acad Sci U S A 105(49):19444-9. [PubMed: 19033462] [MGI Ref ID J:142106]
Furumoto Y; Charles N; Olivera A; Leung WH; Dillahunt S; Sargent JL; Tinsley K; Odom S; Scott E; Wilson TM; Ghoreschi K; Kneilling M; Chen M; Lee DM; Bolland S; Rivera J. 2011. PTEN deficiency in mast cells causes a mastocytosis-like proliferative disease that heightens allergic responses and vascular permeability. Blood 118(20):5466-75. [PubMed: 21926349] [MGI Ref ID J:178784]
Ghosh S; Lau H; Simons BW; Powell JD; Meyers DJ; De Marzo AM; Berman DM; Lotan TL. 2011. PI3K/mTOR signaling regulates prostatic branching morphogenesis. Dev Biol 360(2):329-42. [PubMed: 22015718] [MGI Ref ID J:178714]
Goebbels S; Oltrogge JH; Kemper R; Heilmann I; Bormuth I; Wolfer S; Wichert SP; Mobius W; Liu X; Lappe-Siefke C; Rossner MJ; Groszer M; Suter U; Frahm J; Boretius S; Nave KA. 2010. Elevated phosphatidylinositol 3,4,5-trisphosphate in glia triggers cell-autonomous membrane wrapping and myelination. J Neurosci 30(26):8953-64. [PubMed: 20592216] [MGI Ref ID J:161841]
Goel HL; Chang C; Pursell B; Leav I; Lyle S; Xi HS; Hsieh CC; Adisetiyo H; Roy-Burman P; Coleman IM; Nelson PS; Vessella RL; Davis RJ; Plymate SR; Mercurio AM. 2012. VEGF/neuropilin-2 regulation of Bmi-1 and consequent repression of IGF-IR define a novel mechanism of aggressive prostate cancer. Cancer Discov 2(10):906-21. [PubMed: 22777769] [MGI Ref ID J:193157]
Goertz MJ; Wu Z; Gallardo TD; Hamra FK; Castrillon DH. 2011. Foxo1 is required in mouse spermatogonial stem cells for their maintenance and the initiation of spermatogenesis. J Clin Invest 121(9):3456-66. [PubMed: 21865646] [MGI Ref ID J:178240]
Gregorian C ; Nakashima J ; Le Belle J ; Ohab J ; Kim R ; Liu A ; Smith KB ; Groszer M ; Garcia AD ; Sofroniew MV ; Carmichael ST ; Kornblum HI ; Liu X ; Wu H. 2009. Pten deletion in adult neural stem/progenitor cells enhances constitutive neurogenesis. J Neurosci 29(6):1874-86. [PubMed: 19211894] [MGI Ref ID J:146630]
Gregorian C; Nakashima J; Dry SM; Nghiemphu PL; Smith KB; Ao Y; Dang J; Lawson G; Mellinghoff IK; Mischel PS; Phelps M; Parada LF; Liu X; Sofroniew MV; Eilber FC; Wu H. 2009. PTEN dosage is essential for neurofibroma development and malignant transformation. Proc Natl Acad Sci U S A 106(46):19479-84. [PubMed: 19846776] [MGI Ref ID J:154673]
Groszer M; Erickson R; Scripture-Adams DD; Dougherty JD; Le Belle J; Zack JA; Geschwind DH; Liu X; Kornblum HI; Wu H. 2006. PTEN negatively regulates neural stem cell self-renewal by modulating G0-G1 cell cycle entry. Proc Natl Acad Sci U S A 103(1):111-116. [PubMed: 16373498] [MGI Ref ID J:104566]
Groszer M; Erickson R; Scripture-Adams DD; Lesche R; Trumpp A; Zack JA; Kornblum HI; Liu X; Wu H. 2001. Negative regulation of neural stem/progenitor cell proliferation by the Pten tumor suppressor gene in vivo. Science 294(5549):2186-9. [PubMed: 11691952] [MGI Ref ID J:73255]
Gu Y; Lindner J; Kumar A; Yuan W; Magnuson MA. 2011. Rictor/mTORC2 is essential for maintaining a balance between beta-cell proliferation and cell size. Diabetes 60(3):827-37. [PubMed: 21266327] [MGI Ref ID J:170129]
Guertin DA; Stevens DM; Saitoh M; Kinkel S; Crosby K; Sheen JH; Mullholland DJ; Magnuson MA; Wu H; Sabatini DM. 2009. mTOR complex 2 is required for the development of prostate cancer induced by Pten loss in mice. Cancer Cell 15(2):148-59. [PubMed: 19185849] [MGI Ref ID J:144810]
Guha M; Plescia J; Leav I; Li J; Languino LR; Altieri DC. 2009. Endogenous tumor suppression mediated by PTEN involves survivin gene silencing. Cancer Res 69(12):4954-8. [PubMed: 19470765] [MGI Ref ID J:149666]
Guo W; Lasky JL; Chang CJ; Mosessian S; Lewis X; Xiao Y; Yeh JE; Chen JY; Iruela-Arispe ML; Varella-Garcia M; Wu H. 2008. Multi-genetic events collaboratively contribute to Pten-null leukaemia stem-cell formation. Nature 453(7194):529-33. [PubMed: 18463637] [MGI Ref ID J:135172]
Guo W; Schubbert S; Chen JY; Valamehr B; Mosessian S; Shi H; Dang NH; Garcia C; Theodoro MF; Varella-Garcia M; Wu H. 2011. Suppression of leukemia development caused by PTEN loss. Proc Natl Acad Sci U S A 108(4):1409-14. [PubMed: 21212363] [MGI Ref ID J:168259]
Hand TW; Cui W; Jung YW; Sefik E; Joshi NS; Chandele A; Liu Y; Kaech SM. 2010. Differential effects of STAT5 and PI3K/AKT signaling on effector and memory CD8 T-cell survival. Proc Natl Acad Sci U S A 107(38):16601-6. [PubMed: 20823247] [MGI Ref ID J:164425]
He L; Hou X; Kanel G; Zeng N; Galicia V; Wang Y; Yang J; Wu H; Birnbaum MJ; Stiles BL. 2010. The critical role of AKT2 in hepatic steatosis induced by PTEN loss. Am J Pathol 176(5):2302-8. [PubMed: 20348245] [MGI Ref ID J:160759]
He XC; Yin T; Grindley JC; Tian Q; Sato T; Tao WA; Dirisina R; Porter-Westpfahl KS; Hembree M; Johnson T; Wiedemann LM; Barrett TA; Hood L; Wu H; Li L. 2007. PTEN-deficient intestinal stem cells initiate intestinal polyposis. Nat Genet 39(2):189-98. [PubMed: 17237784] [MGI Ref ID J:118329]
Hill R; Calvopina JH; Kim C; Wang Y; Dawson DW; Donahue TR; Dry S; Wu H. 2010. PTEN loss accelerates KrasG12D-induced pancreatic cancer development. Cancer Res 70(18):7114-24. [PubMed: 20807812] [MGI Ref ID J:164210]
Hill R; Song Y; Cardiff RD; Van Dyke T. 2005. Heterogeneous tumor evolution initiated by loss of pRb function in a preclinical prostate cancer model. Cancer Res 65(22):10243-54. [PubMed: 16288012] [MGI Ref ID J:103408]
Hsieh AC; Liu Y; Edlind MP; Ingolia NT; Janes MR; Sher A; Shi EY; Stumpf CR; Christensen C; Bonham MJ; Wang S; Ren P; Martin M; Jessen K; Feldman ME; Weissman JS; Shokat KM; Rommel C; Ruggero D. 2012. The translational landscape of mTOR signalling steers cancer initiation and metastasis. Nature 485(7396):55-61. [PubMed: 22367541] [MGI Ref ID J:183775]
Hu Z; Wang H; Lee IH; Modi S; Wang X; Du J; Mitch WE. 2010. PTEN inhibition improves muscle regeneration in mice fed a high-fat diet. Diabetes 59(6):1312-20. [PubMed: 20200318] [MGI Ref ID J:169364]
Hubner A; Mulholland DJ; Standen CL; Karasarides M; Cavanagh-Kyros J; Barrett T; Chi H; Greiner DL; Tournier C; Sawyers CL; Flavell RA; Wu H; Davis RJ. 2012. JNK and PTEN cooperatively control the development of invasive adenocarcinoma of the prostate. Proc Natl Acad Sci U S A 109(30):12046-51. [PubMed: 22753496] [MGI Ref ID J:186492]
Hurtz C; Hatzi K; Cerchietti L; Braig M; Park E; Kim YM; Herzog S; Ramezani-Rad P; Jumaa H; Muller MC; Hofmann WK; Hochhaus A; Ye BH; Agarwal A; Druker BJ; Shah NP; Melnick AM; Muschen M. 2011. BCL6-mediated repression of p53 is critical for leukemia stem cell survival in chronic myeloid leukemia. J Exp Med 208(11):2163-74. [PubMed: 21911423] [MGI Ref ID J:178790]
Huse JT; Holland EC. 2009. Genetically engineered mouse models of brain cancer and the promise of preclinical testing. Brain Pathol 19(1):132-43. [PubMed: 19076778] [MGI Ref ID J:173443]
Iwanaga K; Yang Y; Raso MG; Ma L; Hanna AE; Thilaganathan N; Moghaddam S; Evans CM; Li H; Cai WW; Sato M; Minna JD; Wu H; Creighton CJ; Demayo FJ; Wistuba II; Kurie JM. 2008. Pten inactivation accelerates oncogenic K-ras-initiated tumorigenesis in a mouse model of lung cancer. Cancer Res 68(4):1119-27. [PubMed: 18281487] [MGI Ref ID J:131721]
Jagarlamudi K; Liu L; Adhikari D; Reddy P; Idahl A; Ottander U; Lundin E; Liu K. 2009. Oocyte-specific deletion of Pten in mice reveals a stage-specific function of PTEN/PI3K signaling in oocytes in controlling follicular activation. PLoS One 4(7):e6186. [PubMed: 19587782] [MGI Ref ID J:151696]
Jia S; Gao X; Lee SH; Maira SM; Wu X; Stack EC; Signoretti S; Loda M; Zhao JJ; Roberts TM. 2013. Opposing effects of androgen deprivation and targeted therapy on prostate cancer prevention. Cancer Discov 3(1):44-51. [PubMed: 23258246] [MGI Ref ID J:194362]
Jia S; Liu Z; Zhang S; Liu P; Zhang L; Lee SH; Zhang J; Signoretti S; Loda M; Roberts TM; Zhao JJ. 2008. Essential roles of PI(3)K-p110beta in cell growth, metabolism and tumorigenesis. Nature 454(7205):776-9. [PubMed: 18594509] [MGI Ref ID J:138565]
John GB; Gallardo TD; Shirley LJ; Castrillon DH. 2008. Foxo3 is a PI3K-dependent molecular switch controlling the initiation of oocyte growth. Dev Biol 321(1):197-204. [PubMed: 18601916] [MGI Ref ID J:138697]
Joshi A; Ellenson LH. 2011. Adenovirus mediated homozygous endometrial epithelial Pten deletion results in aggressive endometrial carcinoma. Exp Cell Res 317(11):1580-9. [PubMed: 21397598] [MGI Ref ID J:174151]
Jun HJ; Acquaviva J; Chi D; Lessard J; Zhu H; Woolfenden S; Bronson RT; Pfannl R; White F; Housman DE; Iyer L; Whittaker CA; Boskovitz A; Raval A; Charest A. 2012. Acquired MET expression confers resistance to EGFR inhibition in a mouse model of glioblastoma multiforme. Oncogene 31(25):3039-50. [PubMed: 22020333] [MGI Ref ID J:186125]
Kalaitzidis D; Sykes SM; Wang Z; Punt N; Tang Y; Ragu C; Sinha AU; Lane SW; Souza AL; Clish CB; Anastasiou D; Gilliland DG; Scadden DT; Guertin DA; Armstrong SA. 2012. mTOR complex 1 plays critical roles in hematopoiesis and Pten-loss-evoked leukemogenesis. Cell Stem Cell 11(3):429-39. [PubMed: 22958934] [MGI Ref ID J:193428]
Kenerson HL; Yeh MM; Yeung RS. 2011. Tuberous sclerosis complex-1 deficiency attenuates diet-induced hepatic lipid accumulation. PLoS One 6(3):e18075. [PubMed: 21479224] [MGI Ref ID J:171445]
Khodavirdi AC; Song Z; Yang S; Zhong C; Wang S; Wu H; Pritchard C; Nelson PS; Roy-Burman P. 2006. Increased expression of osteopontin contributes to the progression of prostate cancer. Cancer Res 66(2):883-8. [PubMed: 16424021] [MGI Ref ID J:106566]
Kim HS; Woolard K; Lai C; Bauer PO; Maric D; Song H; Li A; Kotliarova S; Zhang W; Fine HA. 2012. Gliomagenesis arising from Pten- and Ink4a/Arf-deficient neural progenitor cells is mediated by the p53-Fbxw7/Cdc4 pathway, which controls c-Myc. Cancer Res 72(22):6065-75. [PubMed: 22986743] [MGI Ref ID J:192887]
Kim J; Eltoum IE; Roh M; Wang J; Abdulkadir SA. 2009. Interactions between cells with distinct mutations in c-MYC and Pten in prostate cancer. PLoS Genet 5(7):e1000542. [PubMed: 19578399] [MGI Ref ID J:151623]
Kim J; Roh M; Doubinskaia I; Algarroba GN; Eltoum IE; Abdulkadir SA. 2012. A mouse model of heterogeneous, c-MYC-initiated prostate cancer with loss of Pten and p53. Oncogene 31(3):322-32. [PubMed: 21685943] [MGI Ref ID J:181074]
Kim TH; Franco HL; Jung SY; Qin J; Broaddus RR; Lydon JP; Jeong JW. 2010. The synergistic effect of Mig-6 and Pten ablation on endometrial cancer development and progression. Oncogene 29(26):3770-80. [PubMed: 20418913] [MGI Ref ID J:162027]
Kinross KM; Montgomery KG; Kleinschmidt M; Waring P; Ivetac I; Tikoo A; Saad M; Hare L; Roh V; Mantamadiotis T; Sheppard KE; Ryland GL; Campbell IG; Gorringe KL; Christensen JG; Cullinane C; Hicks RJ; Pearson RB; Johnstone RW; McArthur GA; Phillips WA. 2012. An activating Pik3ca mutation coupled with Pten loss is sufficient to initiate ovarian tumorigenesis in mice. J Clin Invest 122(2):553-7. [PubMed: 22214849] [MGI Ref ID J:184382]
Klein RD. 2005. The use of genetically engineered mouse models of prostate cancer for nutrition and cancer chemoprevention research. Mutat Res 576(1-2):111-9. [PubMed: 15885713] [MGI Ref ID J:100619]
Klezovitch O; Risk M; Coleman I; Lucas JM; Null M; True LD; Nelson PS; Vasioukhin V. 2008. A causal role for ERG in neoplastic transformation of prostate epithelium. Proc Natl Acad Sci U S A 105(6):2105-10. [PubMed: 18245377] [MGI Ref ID J:131932]
Kurlawalla-Martinez C; Stiles B; Wang Y; Devaskar SU; Kahn BB; Wu H. 2005. Insulin hypersensitivity and resistance to streptozotocin-induced diabetes in mice lacking PTEN in adipose tissue. Mol Cell Biol 25(6):2498-510. [PubMed: 15743841] [MGI Ref ID J:97588]
Kwon CH; Zhao D; Chen J; Alcantara S; Li Y; Burns DK; Mason RP; Lee EY; Wu H; Parada LF. 2008. Pten haploinsufficiency accelerates formation of high-grade astrocytomas. Cancer Res 68(9):3286-94. [PubMed: 18451155] [MGI Ref ID J:134611]
Lague MN; Detmar J; Paquet M; Boyer A; Richards JS; Adamson SL; Boerboom D. 2010. Decidual PTEN expression is required for trophoblast invasion in the mouse. Am J Physiol Endocrinol Metab 299(6):E936-46. [PubMed: 20858757] [MGI Ref ID J:170203]
Lague MN; Paquet M; Fan HY; Kaartinen MJ; Chu S; Jamin SP; Behringer RR; Fuller PJ; Mitchell A; Dore M; Huneault LM; Richards JS; Boerboom D. 2008. Synergistic effects of Pten loss and WNT/CTNNB1 signaling pathway activation in ovarian granulosa cell tumor development and progression. Carcinogenesis 29(11):2062-72. [PubMed: 18687666] [MGI Ref ID J:142150]
Langlois MJ; Roy SA; Auclair BA; Jones C; Boudreau F; Carrier JC; Rivard N; Perreault N. 2009. Epithelial phosphatase and tensin homolog regulates intestinal architecture and secretory cell commitment and acts as a modifier gene in neoplasia. FASEB J 23(6):1835-44. [PubMed: 19168705] [MGI Ref ID J:150553]
Leav I; Plescia J; Goel HL; Li J; Jiang Z; Cohen RJ; Languino LR; Altieri DC. 2010. Cytoprotective mitochondrial chaperone TRAP-1 as a novel molecular target in localized and metastatic prostate cancer. Am J Pathol 176(1):393-401. [PubMed: 19948822] [MGI Ref ID J:156382]
Lee JY; Nakada D; Yilmaz OH; Tothova Z; Joseph NM; Lim MS; Gilliland DG; Morrison SJ. 2010. mTOR activation induces tumor suppressors that inhibit leukemogenesis and deplete hematopoietic stem cells after Pten deletion. Cell Stem Cell 7(5):593-605. [PubMed: 21040901] [MGI Ref ID J:167537]
Lehtinen MK; Zappaterra MW; Chen X; Yang YJ; Hill AD; Lun M; Maynard T; Gonzalez D; Kim S; Ye P; D'Ercole AJ; Wong ET; LaMantia AS; Walsh CA. 2011. The cerebrospinal fluid provides a proliferative niche for neural progenitor cells. Neuron 69(5):893-905. [PubMed: 21382550] [MGI Ref ID J:174742]
Lei L; Sonabend AM; Guarnieri P; Soderquist C; Ludwig T; Rosenfeld S; Bruce JN; Canoll P. 2011. Glioblastoma Models Reveal the Connection between Adult Glial Progenitors and the Proneural Phenotype. PLoS One 6(5):e20041. [PubMed: 21625383] [MGI Ref ID J:172585]
Lesche R; Groszer M; Gao J; Wang Y; Messing A; Sun H; Liu X; Wu H. 2002. Cre/loxP-mediated inactivation of the murine Pten tumor suppressor gene. Genesis 32(2):148-9. [PubMed: 11857804] [MGI Ref ID J:75117]
Li G; Robinson GW; Lesche R; Martinez-Diaz H; Jiang Z; Rozengurt N; Wagner KU; Wu DC; Lane TF; Liu X; Hennighausen L; Wu H. 2002. Conditional loss of PTEN leads to precocious development and neoplasia in the mammary gland. Development 129(17):4159-70. [PubMed: 12163417] [MGI Ref ID J:78415]
Li Y; Jia Y; Pichavant M; Loison F; Sarraj B; Kasorn A; You J; Robson BE; Umetsu DT; Mizgerd JP; Ye K; Luo HR. 2009. Targeted deletion of tumor suppressor PTEN augments neutrophil function and enhances host defense in neutropenia-associated pneumonia. Blood 113(20):4930-41. [PubMed: 19286998] [MGI Ref ID J:148947]
Liao CP; Adisetiyo H; Liang M; Roy-Burman P. 2010. Cancer-associated fibroblasts enhance the gland-forming capability of prostate cancer stem cells. Cancer Res 70(18):7294-303. [PubMed: 20807814] [MGI Ref ID J:164208]
Liao CP; Zhong C; Saribekyan G; Bading J; Park R; Conti PS; Moats R; Berns A; Shi W; Zhou Z; Nikitin AY; Roy-Burman P. 2007. Mouse models of prostate adenocarcinoma with the capacity to monitor spontaneous carcinogenesis by bioluminescence or fluorescence. Cancer Res 67(15):7525-33. [PubMed: 17671224] [MGI Ref ID J:123911]
Liu K; Lu Y; Lee JK; Samara R; Willenberg R; Sears-Kraxberger I; Tedeschi A; Park KK; Jin D; Cai B; Xu B; Connolly L; Steward O; Zheng B; He Z. 2010. PTEN deletion enhances the regenerative ability of adult corticospinal neurons. Nat Neurosci 13(9):1075-81. [PubMed: 20694004] [MGI Ref ID J:165283]
Lu TL; Chang JL; Liang CC; You LR; Chen CM. 2007. Tumor spectrum, tumor latency and tumor incidence of the pten-deficient mice. PLoS ONE 2(11):e1237. [PubMed: 18043744] [MGI Ref ID J:130367]
Lukacs RU; Memarzadeh S; Wu H; Witte ON. 2010. Bmi-1 is a crucial regulator of prostate stem cell self-renewal and malignant transformation. Cell Stem Cell 7(6):682-93. [PubMed: 21112563] [MGI Ref ID J:168487]
Magee JA; Ikenoue T; Nakada D; Lee JY; Guan KL; Morrison SJ. 2012. Temporal changes in PTEN and mTORC2 regulation of hematopoietic stem cell self-renewal and leukemia suppression. Cell Stem Cell 11(3):415-28. [PubMed: 22958933] [MGI Ref ID J:191342]
Martin P; Liu YN; Pierce R; Abou-Kheir W; Casey O; Seng V; Camacho D; Simpson RM; Kelly K. 2011. Prostate Epithelial Pten/TP53 Loss Leads to Transformation of Multipotential Progenitors and Epithelial to Mesenchymal Transition. Am J Pathol 179(1):422-35. [PubMed: 21703421] [MGI Ref ID J:173998]
McMahon J; Huang X; Yang J; Komatsu M; Yue Z; Qian J; Zhu X; Huang Y. 2012. Impaired autophagy in neurons after disinhibition of mammalian target of rapamycin and its contribution to epileptogenesis. J Neurosci 32(45):15704-14. [PubMed: 23136410] [MGI Ref ID J:192244]
Michaud J; Im DS; Hla T. 2010. Inhibitory role of sphingosine 1-phosphate receptor 2 in macrophage recruitment during inflammation. J Immunol 184(3):1475-83. [PubMed: 20042570] [MGI Ref ID J:159530]
Miletic AV; Anzelon-Mills AN; Mills DM; Omori SA; Pedersen IM; Shin DM; Ravetch JV; Bolland S; Morse HC 3rd; Rickert RC. 2010. Coordinate suppression of B cell lymphoma by PTEN and SHIP phosphatases. J Exp Med 207(11):2407-20. [PubMed: 20956547] [MGI Ref ID J:166155]
Ming M; Feng L; Shea CR; Soltani K; Zhao B; Han W; Smart RC; Trempus CS; He YY. 2011. PTEN Positively Regulates UVB-Induced DNA Damage Repair. Cancer Res 71(15):5287-95. [PubMed: 21771908] [MGI Ref ID J:174190]
Ming M; Shea CR; Feng L; Soltani K; He YY. 2011. UVA induces lesions resembling seborrheic keratoses in mice with keratinocyte-specific PTEN downregulation. J Invest Dermatol 131(7):1583-6. [PubMed: 21390050] [MGI Ref ID J:182077]
Mondal S; Ghosh-Roy S; Loison F; Li Y; Jia Y; Harris C; Williams DA; Luo HR. 2011. PTEN negatively regulates engulfment of apoptotic cells by modulating activation of Rac GTPase. J Immunol 187(11):5783-94. [PubMed: 22043008] [MGI Ref ID J:179722]
Mulholland DJ; Kobayashi N; Ruscetti M; Zhi A; Tran LM; Huang J; Gleave M; Wu H. 2012. Pten loss and RAS/MAPK activation cooperate to promote EMT and metastasis initiated from prostate cancer stem/progenitor cells. Cancer Res 72(7):1878-89. [PubMed: 22350410] [MGI Ref ID J:184935]
Mulholland DJ; Tran LM; Li Y; Cai H; Morim A; Wang S; Plaisier S; Garraway IP; Huang J; Graeber TG; Wu H. 2011. Cell Autonomous Role of PTEN in Regulating Castration-Resistant Prostate Cancer Growth. Cancer Cell 19(6):792-804. [PubMed: 21620777] [MGI Ref ID J:172730]
Mulholland DJ; Xin L; Morim A; Lawson D; Witte O; Wu H. 2009. Lin-Sca-1+CD49fhigh stem/progenitors are tumor-initiating cells in the Pten-null prostate cancer model. Cancer Res 69(22):8555-62. [PubMed: 19887604] [MGI Ref ID J:154444]
Mullany LK; Fan HY; Liu Z; White LD; Marshall A; Gunaratne P; Anderson ML; Creighton CJ; Xin L; Deavers M; Wong KK; Richards JS. 2011. Molecular and functional characteristics of ovarian surface epithelial cells transformed by KrasG12D and loss of Pten in a mouse model in vivo. Oncogene 30(32):3522-36. [PubMed: 21423204] [MGI Ref ID J:174632]
Nahar R; Ramezani-Rad P; Mossner M; Duy C; Cerchietti L; Geng H; Dovat S; Jumaa H; Ye BH; Melnick A; Muschen M. 2011. Pre-B cell receptor-mediated activation of BCL6 induces pre-B cell quiescence through transcriptional repression of MYC. Blood 118(15):4174-8. [PubMed: 21856866] [MGI Ref ID J:178400]
Napoli E; Ross-Inta C; Wong S; Hung C; Fujisawa Y; Sakaguchi D; Angelastro J; Omanska-Klusek A; Schoenfeld R; Giulivi C. 2012. Mitochondrial dysfunction in Pten haplo-insufficient mice with social deficits and repetitive behavior: interplay between Pten and p53. PLoS One 7(8):e42504. [PubMed: 22900024] [MGI Ref ID J:189934]
Narayanan NK; Nargi D; Randolph C; Narayanan BA. 2009. Liposome encapsulation of curcumin and resveratrol in combination reduces prostate cancer incidence in PTEN knockout mice. Int J Cancer 125(1):1-8. [PubMed: 19326431] [MGI Ref ID J:151360]
Omori SA; Cato MH; Anzelon-Mills A; Puri KD; Shapiro-Shelef M; Calame K; Rickert RC. 2006. Regulation of class-switch recombination and plasma cell differentiation by phosphatidylinositol 3-kinase signaling. Immunity 25(4):545-57. [PubMed: 17000121] [MGI Ref ID J:114881]
Parapuram SK; Shi-wen X; Elliott C; Welch ID; Jones H; Baron M; Denton CP; Abraham DJ; Leask A. 2011. Loss of PTEN expression by dermal fibroblasts causes skin fibrosis. J Invest Dermatol 131(10):1996-2003. [PubMed: 21654839] [MGI Ref ID J:182199]
Peng C; Chen Y; Yang Z; Zhang H; Osterby L; Rosmarin AG; Li S. 2010. PTEN is a tumor suppressor in CML stem cells and BCR-ABL-induced leukemias in mice. Blood 115(3):626-35. [PubMed: 19965668] [MGI Ref ID J:156831]
Perry JM; He XC; Sugimura R; Grindley JC; Haug JS; Ding S; Li L. 2011. Cooperation between both Wnt/{beta}-catenin and PTEN/PI3K/Akt signaling promotes primitive hematopoietic stem cell self-renewal and expansion. Genes Dev 25(18):1928-42. [PubMed: 21890648] [MGI Ref ID J:176204]
Powers SE; Mandal M; Matsuda S; Miletic AV; Cato MH; Tanaka A; Rickert RC; Koyasu S; Clark MR. 2012. Subnuclear cyclin D3 compartments and the coordinated regulation of proliferation and immunoglobulin variable gene repression. J Exp Med 209(12):2199-213. [PubMed: 23109711] [MGI Ref ID J:190888]
Puig I; Champeval D; De Santa Barbara P; Jaubert F; Lyonnet S; Larue L. 2009. Deletion of Pten in the mouse enteric nervous system induces ganglioneuromatosis and mimics intestinal pseudoobstruction. J Clin Invest 119(12):3586-96. [PubMed: 19884655] [MGI Ref ID J:155110]
Puzio-Kuter AM; Castillo-Martin M; Kinkade CW; Wang X; Shen TH; Matos T; Shen MM; Cordon-Cardo C; Abate-Shen C. 2009. Inactivation of p53 and Pten promotes invasive bladder cancer. Genes Dev 23(6):675-80. [PubMed: 19261747] [MGI Ref ID J:146760]
Qian J; Ling S; Castillo AC; Long B; Birnbaum Y; Ye Y. 2012. Regulation of phosphatase and tensin homolog on chromosome 10 in response to hypoxia. Am J Physiol Heart Circ Physiol 302(9):H1806-17. [PubMed: 22367504] [MGI Ref ID J:186577]
Qin J; Wu SP; Creighton CJ; Dai F; Xie X; Cheng CM; Frolov A; Ayala G; Lin X; Feng XH; Ittmann MM; Tsai SJ; Tsai MJ; Tsai SY. 2013. COUP-TFII inhibits TGF-beta-induced growth barrier to promote prostate tumorigenesis. Nature 493(7431):236-40. [PubMed: 23201680] [MGI Ref ID J:194187]
Reddy P; Liu L; Adhikari D; Jagarlamudi K; Rajareddy S; Shen Y; Du C; Tang W; Hamalainen T; Peng SL; Lan ZJ; Cooney AJ; Huhtaniemi I; Liu K. 2008. Oocyte-specific deletion of Pten causes premature activation of the primordial follicle pool. Science 319(5863):611-3. [PubMed: 18239123] [MGI Ref ID J:131827]
Richards JS; Fan HY; Liu Z; Tsoi M; Lague MN; Boyer A; Boerboom D. 2012. Either Kras activation or Pten loss similarly enhance the dominant-stable CTNNB1-induced genetic program to promote granulosa cell tumor development in the ovary and testis. Oncogene 31(12):1504-20. [PubMed: 21860425] [MGI Ref ID J:186144]
Ricke EA; Williams K; Lee YF; Couto S; Wang Y; Hayward SW; Cunha GR; Ricke WA. 2012. Androgen hormone action in prostatic carcinogenesis: stromal androgen receptors mediate prostate cancer progression, malignant transformation and metastasis. Carcinogenesis 33(7):1391-8. [PubMed: 22535887] [MGI Ref ID J:190775]
Ruan H; Li J; Ren S; Gao J; Li G; Kim R; Wu H; Wang Y. 2009. Inducible and cardiac specific PTEN inactivation protects ischemia/reperfusion injury. J Mol Cell Cardiol 46(2):193-200. [PubMed: 19038262] [MGI Ref ID J:149180]
Sakagami K; Chen B; Nusinowitz S; Wu H; Yang XJ. 2012. PTEN regulates retinal interneuron morphogenesis and synaptic layer formation. Mol Cell Neurosci 49(2):171-83. [PubMed: 22155156] [MGI Ref ID J:191532]
Sarraj B; Massberg S; Li Y; Kasorn A; Subramanian K; Loison F; Silberstein LE; von Andrian U; Luo HR. 2009. Myeloid-specific deletion of tumor suppressor PTEN augments neutrophil transendothelial migration during inflammation. J Immunol 182(11):7190-200. [PubMed: 19454716] [MGI Ref ID J:148853]
Sengupta P; Basu S; Soni S; Pandey A; Roy B; Oh MS; Chin KT; Paraskar AS; Sarangi S; Connor Y; Sabbisetti VS; Kopparam J; Kulkarni A; Muto K; Amarasiriwardena C; Jayawardene I; Lupoli N; Dinulescu DM; Bonventre JV; Mashelkar RA; Sengupta S. 2012. Cholesterol-tethered platinum II-based supramolecular nanoparticle increases antitumor efficacy and reduces nephrotoxicity. Proc Natl Acad Sci U S A 109(28):11294-9. [PubMed: 22733767] [MGI Ref ID J:186400]
Song H; Yao E; Lin C; Gacayan R; Chen MH; Chuang PT. 2012. Functional characterization of pulmonary neuroendocrine cells in lung development, injury, and tumorigenesis. Proc Natl Acad Sci U S A 109(43):17531-6. [PubMed: 23047698] [MGI Ref ID J:190366]
Squarize CH; Castilho RM; Gutkind JS. 2008. Chemoprevention and treatment of experimental Cowden's disease by mTOR inhibition with rapamycin. Cancer Res 68(17):7066-72. [PubMed: 18757421] [MGI Ref ID J:138927]
Srinivasan L; Sasaki Y; Calado DP; Zhang B; Paik JH; DePinho RA; Kutok JL; Kearney JF; Otipoby KL; Rajewsky K. 2009. PI3 kinase signals BCR-dependent mature B cell survival. Cell 139(3):573-86. [PubMed: 19879843] [MGI Ref ID J:157297]
Stanger BZ; Stiles B; Lauwers GY; Bardeesy N; Mendoza M; Wang Y; Greenwood A; Cheng KH; McLaughlin M; Brown D; Depinho RA; Wu H; Melton DA; Dor Y. 2005. Pten constrains centroacinar cell expansion and malignant transformation in the pancreas. Cancer Cell 8(3):185-95. [PubMed: 16169464] [MGI Ref ID J:102226]
Stiles B; Wang Y; Stahl A; Bassilian S; Lee WP; Kim YJ; Sherwin R; Devaskar S; Lesche R; Magnuson MA; Wu H. 2004. Liver-specific deletion of negative regulator Pten results in fatty liver and insulin hypersensitivity [corrected]. Proc Natl Acad Sci U S A 101(7):2082-7. [PubMed: 14769918] [MGI Ref ID J:88441]
Stiles BL; Kuralwalla-Martinez C; Guo W; Gregorian C; Wang Y; Tian J; Magnuson MA; Wu H. 2006. Selective deletion of Pten in pancreatic beta cells leads to increased islet mass and resistance to STZ-induced diabetes. Mol Cell Biol 26(7):2772-81. [PubMed: 16537919] [MGI Ref ID J:106937]
Subramanian KK; Jia Y; Zhu D; Simms BT; Jo H; Hattori H; You J; Mizgerd JP; Luo HR. 2007. Tumor suppressor PTEN is a physiologic suppressor of chemoattractant-mediated neutrophil functions. Blood 109(9):4028-37. [PubMed: 17202315] [MGI Ref ID J:145331]
Sun X; Jackson L; Dey SK; Daikoku T. 2009. In pursuit of leucine-rich repeat-containing G protein-coupled receptor-5 regulation and function in the uterus. Endocrinology 150(11):5065-73. [PubMed: 19797400] [MGI Ref ID J:157315]
Svensson RU; Haverkamp JM; Thedens DR; Cohen MB; Ratliff TL; Henry MD. 2011. Slow disease progression in a C57BL/6 pten-deficient mouse model of prostate cancer. Am J Pathol 179(1):502-12. [PubMed: 21703427] [MGI Ref ID J:173997]
Tandon P; Gallo CA; Khatri S; Barger JF; Yepiskoposyan H; Plas DR. 2011. Requirement for ribosomal protein S6 kinase 1 to mediate glycolysis and apoptosis resistance induced by Pten deficiency. Proc Natl Acad Sci U S A 108(6):2361-5. [PubMed: 21262837] [MGI Ref ID J:169097]
Tang S; Moore ML; Grayson JM; Dubey P. 2012. Increased CD8+ T-cell function following castration and immunization is countered by parallel expansion of regulatory T cells. Cancer Res 72(8):1975-85. [PubMed: 22374980] [MGI Ref ID J:185631]
Tanwar PS; Commandeur AE; Zhang L; Taketo MM; Teixeira JM. 2012. The Mullerian inhibiting substance type 2 receptor suppresses tumorigenesis in testes with sustained beta-catenin signaling. Carcinogenesis 33(12):2351-61. [PubMed: 22962306] [MGI Ref ID J:193300]
Tanwar PS; Kaneko-Tarui T; Zhang L; Tanaka Y; Crum CP; Teixeira JM. 2012. Stromal liver kinase B1 [STK11] signaling loss induces oviductal adenomas and endometrial cancer by activating mammalian Target of Rapamycin Complex 1. PLoS Genet 8(8):e1002906. [PubMed: 22916036] [MGI Ref ID J:188124]
Tanwar PS; Kaneko-Tarui T; Zhang L; Teixeira JM. 2012. Altered LKB1/AMPK/TSC1/TSC2/mTOR signaling causes disruption of Sertoli cell polarity and spermatogenesis. Hum Mol Genet 21(20):4394-405. [PubMed: 22791749] [MGI Ref ID J:187754]
Tanwar PS; Zhang L; Kaneko-Tarui T; Curley MD; Taketo MM; Rani P; Roberts DJ; Teixeira JM. 2011. Mammalian Target of Rapamycin Is a Therapeutic Target for Murine Ovarian Endometrioid Adenocarcinomas with Dysregulated Wnt/beta-Catenin and PTEN. PLoS One 6(6):e20715. [PubMed: 21695255] [MGI Ref ID J:174289]
Thomsen MK; Ambroisine L; Wynn S; Cheah KS; Foster CS; Fisher G; Berney DM; Moller H; Reuter VE; Scardino P; Cuzick J; Ragavan N; Singh PB; Martin FL; Butler CM; Cooper CS; Swain A. 2010. SOX9 elevation in the prostate promotes proliferation and cooperates with PTEN loss to drive tumor formation. Cancer Res 70(3):979-87. [PubMed: 20103652] [MGI Ref ID J:156856]
Ting MC; Liao CP; Yan C; Jia L; Groshen S; Frenkel B; Roy-Burman P; Coetzee GA; Maxson R. 2012. An enhancer from the 8q24 prostate cancer risk region is sufficient to direct reporter gene expression to a subset of prostate stem-like epithelial cells in transgenic mice. Dis Model Mech 5(3):366-74. [PubMed: 22279083] [MGI Ref ID J:181487]
Tiozzo C; De Langhe S; Yu M; Londhe VA; Carraro G; Li M; Li C; Xing Y; Anderson S; Borok Z; Bellusci S; Minoo P. 2009. Deletion of Pten expands lung epithelial progenitor pools and confers resistance to airway injury. Am J Respir Crit Care Med 180(8):701-12. [PubMed: 19574443] [MGI Ref ID J:167962]
Vitari AC; Leong KG; Newton K; Yee C; O'Rourke K; Liu J; Phu L; Vij R; Ferrando R; Couto SS; Mohan S; Pandita A; Hongo JA; Arnott D; Wertz IE; Gao WQ; French DM; Dixit VM. 2011. COP1 is a tumour suppressor that causes degradation of ETS transcription factors. Nature 474(7351):403-6. [PubMed: 21572435] [MGI Ref ID J:172653]
Vivanco I; Rohle D; Versele M; Iwanami A; Kuga D; Oldrini B; Tanaka K; Dang J; Kubek S; Palaskas N; Hsueh T; Evans M; Mulholland D; Wolle D; Rajasekaran S; Rajasekaran A; Liau LM; Cloughesy TF; Dikic I; Brennan C; Wu H; Mischel PS; Perera T; Mellinghoff IK. 2010. The phosphatase and tensin homolog regulates epidermal growth factor receptor (EGFR) inhibitor response by targeting EGFR for degradation. Proc Natl Acad Sci U S A 107(14):6459-64. [PubMed: 20308550] [MGI Ref ID J:159321]
Wang J; Kobayashi T; Floc'h N; Kinkade CW; Aytes A; Dankort D; Lefebvre C; Mitrofanova A; Cardiff RD; McMahon M; Califano A; Shen MM; Abate-Shen C. 2012. B-Raf activation cooperates with PTEN loss to drive c-Myc expression in advanced prostate cancer. Cancer Res 72(18):4765-76. [PubMed: 22836754] [MGI Ref ID J:191327]
Wang L; Liu Y; Yan Lu S; Nguyen KT; Schroer SA; Suzuki A; Mak TW; Gaisano H; Woo M. 2010. Deletion of Pten in pancreatic ss-cells protects against deficient ss-cell mass and function in mouse models of type 2 diabetes. Diabetes 59(12):3117-26. [PubMed: 20852026] [MGI Ref ID J:170206]
Wang Q; Li SH; Wang H; Xiao Y; Sahin O; Brady SW; Li P; Ge H; Jaffee EM; Muller WJ; Hortobagyi GN; Yu D. 2012. Concomitant targeting of tumor cells and induction of T-cell response synergizes to effectively inhibit trastuzumab-resistant breast cancer. Cancer Res 72(17):4417-28. [PubMed: 22773664] [MGI Ref ID J:191018]
Wang S; Gao J; Lei Q; Rozengurt N; Pritchard C; Jiao J; Thomas GV; Li G; Roy-Burman P; Nelson PS; Liu X; Wu H. 2003. Prostate-specific deletion of the murine Pten tumor suppressor gene leads to metastatic prostate cancer. Cancer Cell 4(3):209-21. [PubMed: 14522255] [MGI Ref ID J:93902]
Wang S; Garcia AJ; Wu M; Lawson DA; Witte ON; Wu H. 2006. Pten deletion leads to the expansion of a prostatic stem/progenitor cell subpopulation and tumor initiation. Proc Natl Acad Sci U S A 103(5):1480-5. [PubMed: 16432235] [MGI Ref ID J:105995]
Wang S; Wu J; Suburu J; Gu Z; Cai J; Axanova LS; Cramer SD; Thomas MJ; Perry DL; Edwards IJ; Mucci LA; Sinnott JA; Loda MF; Sui G; Berquin IM; Chen YQ. 2012. Effect of dietary polyunsaturated fatty acids on castration-resistant Pten-null prostate cancer. Carcinogenesis 33(2):404-12. [PubMed: 22159221] [MGI Ref ID J:181111]
Wang X; Kruithof-de Julio M; Economides KD; Walker D; Yu H; Halili MV; Hu YP; Price SM; Abate-Shen C; Shen MM. 2009. A luminal epithelial stem cell that is a cell of origin for prostate cancer. Nature 461(7263):495-500. [PubMed: 19741607] [MGI Ref ID J:153425]
Wang ZA; Mitrofanova A; Bergren SK; Abate-Shen C; Cardiff RD; Califano A; Shen MM. 2013. Lineage analysis of basal epithelial cells reveals their unexpected plasticity and supports a cell-of-origin model for prostate cancer heterogeneity. Nat Cell Biol 15(3):274-83. [PubMed: 23434823] [MGI Ref ID J:195200]
Weng Z; Li D; Zhang L; Chen J; Ruan C; Chen G; Gartner TK; Liu J. 2010. PTEN regulates collagen-induced platelet activation. Blood 116(14):2579-81. [PubMed: 20554973] [MGI Ref ID J:165893]
Wey S; Luo B; Tseng CC; Ni M; Zhou H; Fu Y; Bhojwani D; Carroll WL; Lee AS. 2012. Inducible knockout of GRP78/BiP in the hematopoietic system suppresses Pten-null leukemogenesis and AKT oncogenic signaling. Blood 119(3):817-25. [PubMed: 21937694] [MGI Ref ID J:181587]
Woolfenden S; Zhu H; Charest A. 2009. A Cre/LoxP conditional luciferase reporter transgenic mouse for bioluminescence monitoring of tumorigenesis. Genesis 47(10):659-666. [PubMed: 19603508] [MGI Ref ID J:153565]
Xiao C; Srinivasan L; Calado DP; Patterson HC; Zhang B; Wang J; Henderson JM; Kutok JL; Rajewsky K. 2008. Lymphoproliferative disease and autoimmunity in mice with increased miR-17-92 expression in lymphocytes. Nat Immunol 9(4):405-14. [PubMed: 18327259] [MGI Ref ID J:133215]
Xing Y; Li C; Hu L; Tiozzo C; Li M; Chai Y; Bellusci S; Anderson S; Minoo P. 2008. Mechanisms of TGFbeta inhibition of LUNG endodermal morphogenesis: the role of TbetaRII, Smads, Nkx2.1 and Pten. Dev Biol 320(2):340-50. [PubMed: 18602626] [MGI Ref ID J:138200]
Xing Y; Li C; Li A; Sridurongrit S; Tiozzo C; Bellusci S; Borok Z; Kaartinen V; Minoo P. 2010. Signaling via Alk5 controls the ontogeny of lung Clara cells. Development 137(5):825-33. [PubMed: 20147383] [MGI Ref ID J:157922]
Xu X; Ehdaie B; Ohara N; Yoshino T; Deng CX. 2010. Synergistic action of Smad4 and Pten in suppressing pancreatic ductal adenocarcinoma formation in mice. Oncogene 29(5):674-86. [PubMed: 19901970] [MGI Ref ID J:157020]
Xu X; Kobayashi S; Qiao W; Li C; Xiao C; Radaeva S; Stiles B; Wang RH; Ohara N; Yoshino T; LeRoith D; Torbenson MS; Gores GJ; Wu H; Gao B; Deng CX. 2006. Induction of intrahepatic cholangiocellular carcinoma by liver-specific disruption of Smad4 and Pten in mice. J Clin Invest 116(7):1843-52. [PubMed: 16767220] [MGI Ref ID J:111718]
Yang Y; Iwanaga K; Raso MG; Wislez M; Hanna AE; Wieder ED; Molldrem JJ; Wistuba II; Powis G; Demayo FJ; Kim CF; Kurie JM. 2008. Phosphatidylinositol 3-kinase mediates bronchioalveolar stem cell expansion in mouse models of oncogenic K-ras-induced lung cancer. PLoS ONE 3(5):e2220. [PubMed: 18493606] [MGI Ref ID J:136369]
Yang ZF; Zhang H; Ma L; Peng C; Chen Y; Wang J; Green MR; Li S; Rosmarin AG. 2013. GABP transcription factor is required for development of chronic myelogenous leukemia via its control of PRKD2. Proc Natl Acad Sci U S A 110(6):2312-7. [PubMed: 23345428] [MGI Ref ID J:194335]
Yao D; Alexander CL; Quinn JA; Chan WC; Wu H; Greenhalgh DA. 2008. Fos cooperation with PTEN loss elicits keratoacanthoma not carcinoma, owing to p53/p21 WAF-induced differentiation triggered by GSK3beta inactivation and reduced AKT activity. J Cell Sci 121(Pt 10):1758-69. [PubMed: 18445683] [MGI Ref ID J:138532]
Yao D; Alexander CL; Quinn JA; Porter MJ; Wu H; Greenhalgh DA. 2006. PTEN loss promotes rasHa-mediated papillomatogenesis via dual up-regulation of AKT activity and cell cycle deregulation but malignant conversion proceeds via PTEN-associated pathways. Cancer Res 66(3):1302-12. [PubMed: 16452183] [MGI Ref ID J:106683]
Yilmaz OH; Valdez R; Theisen BK; Guo W; Ferguson DO; Wu H; Morrison SJ. 2006. Pten dependence distinguishes haematopoietic stem cells from leukaemia-initiating cells. Nature 441(7092):475-82. [PubMed: 16598206] [MGI Ref ID J:109085]
Yoo LI; Liu DW; Le Vu S; Bronson RT; Wu H; Yuan J. 2006. Pten deficiency activates distinct downstream signaling pathways in a tissue-specific manner. Cancer Res 66(4):1929-39. [PubMed: 16488991] [MGI Ref ID J:106662]
Yue Q; Groszer M; Gil JS; Berk AJ; Messing A; Wu H; Liu X. 2005. PTEN deletion in Bergmann glia leads to premature differentiation and affects laminar organization. Development 132(14):3281-91. [PubMed: 15944184] [MGI Ref ID J:100428]
Zeiser R; Leveson-Gower DB; Zambricki EA; Kambham N; Beilhack A; Loh J; Hou JZ; Negrin RS. 2008. Differential impact of mammalian target of rapamycin inhibition on CD4+CD25+Foxp3+ regulatory T cells compared with conventional CD4+ T cells. Blood 111(1):453-62. [PubMed: 17967941] [MGI Ref ID J:130295]
Zhang J; Grindley JC; Yin T; Jayasinghe S; He XC; Ross JT; Haug JS; Rupp D; Porter-Westpfahl KS; Wiedemann LM; Wu H; Li L. 2006. PTEN maintains haematopoietic stem cells and acts in lineage choice and leukaemia prevention. Nature 441(7092):518-22. [PubMed: 16633340] [MGI Ref ID J:109084]
Zhang L; Sun ZJ; Bian Y; Kulkarni AB. 2013. MicroRNA-135b acts as a tumor promoter by targeting the hypoxia-inducible factor pathway in genetically defined mouse model of head and neck squamous cell carcinoma. Cancer Lett 331(2):230-8. [PubMed: 23340180] [MGI Ref ID J:194341]
Zhang Q; Liu S; Ge D; Zhang Q; Xue Y; Xiong Z; Abdel-Mageed AB; Myers L; Hill SM; Rowan BG; Sartor O; Melamed J; Chen Z; You Z. 2012. Interleukin-17 promotes formation and growth of prostate adenocarcinoma in mouse models. Cancer Res 72(10):2589-99. [PubMed: 22461511] [MGI Ref ID J:189341]
Zhang W; Zhu J; Efferson CL; Ware C; Tammam J; Angagaw M; Laskey J; Bettano KA; Kasibhatla S; Reilly JF; Sur C; Majumder PK. 2009. Inhibition of tumor growth progression by antiandrogens and mTOR inhibitor in a Pten-deficient mouse model of prostate cancer. Cancer Res 69(18):7466-72. [PubMed: 19738074] [MGI Ref ID J:152681]
Zheng W; Gorre N; Shen Y; Noda T; Ogawa W; Lundin E; Liu K. 2010. Maternal phosphatidylinositol 3-kinase signalling is crucial for embryonic genome activation and preimplantation embryogenesis. EMBO Rep 11(11):890-5. [PubMed: 20930845] [MGI Ref ID J:165798]
Zhong C; Saribekyan G; Liao CP; Cohen MB; Roy-Burman P. 2006. Cooperation between FGF8b overexpression and PTEN deficiency in prostate tumorigenesis. Cancer Res 66(4):2188-94. [PubMed: 16489020] [MGI Ref ID J:106650]
Zhu D; Hattori H; Jo H; Jia Y; Subramanian KK; Loison F; You J; Le Y; Honczarenko M; Silberstein L; Luo HR. 2006. Deactivation of phosphatidylinositol 3,4,5-trisphosphate/Akt signaling mediates neutrophil spontaneous death. Proc Natl Acad Sci U S A 103(40):14836-41. [PubMed: 16988010] [MGI Ref ID J:114699]
Zhu H; Acquaviva J; Ramachandran P; Boskovitz A; Woolfenden S; Pfannl R; Bronson RT; Chen JW; Weissleder R; Housman DE; Charest A. 2009. Oncogenic EGFR signaling cooperates with loss of tumor suppressor gene functions in gliomagenesis. Proc Natl Acad Sci U S A 106(8):2712-6. [PubMed: 19196966] [MGI Ref ID J:146494]
Zhu HH; Ji K; Alderson N; He Z; Li S; Liu W; Zhang DE; Li L; Feng GS. 2011. Kit-Shp2-Kit signaling acts to maintain a functional hematopoietic stem and progenitor cell pool. Blood 117(20):5350-61. [PubMed: 21450902] [MGI Ref ID J:177959]
Bosenberg M; Muthusamy V; Curley DP; Wang Z; Hobbs C; Nelson B; Nogueira C; Horner JW 2nd; Depinho R; Chin L. 2006. Characterization of melanocyte-specific inducible Cre recombinase transgenic mice. Genesis 44(5):262-7. [PubMed: 16676322] [MGI Ref ID J:110143]
Burd CE; Sorrentino JA; Clark KS; Darr DB; Krishnamurthy J; Deal AM; Bardeesy N; Castrillon DH; Beach DH; Sharpless NE. 2013. Monitoring tumorigenesis and senescence in vivo with a p16(INK4a)-luciferase model. Cell 152(1-2):340-51. [PubMed: 23332765] [MGI Ref ID J:193498]
Damsky WE; Curley DP; Santhanakrishnan M; Rosenbaum LE; Platt JT; Gould Rothberg BE; Taketo MM; Dankort D; Rimm DL; McMahon M; Bosenberg M. 2011. beta-Catenin Signaling Controls Metastasis in Braf-Activated Pten-Deficient Melanomas. Cancer Cell 20(6):741-54. [PubMed: 22172720] [MGI Ref ID J:178598]
Hari L; Miescher I; Shakhova O; Suter U; Chin L; Taketo M; Richardson WD; Kessaris N; Sommer L. 2012. Temporal control of neural crest lineage generation by Wnt/beta-catenin signaling. Development 139(12):2107-17. [PubMed: 22573620] [MGI Ref ID J:185553]
Held MA; Curley DP; Dankort D; McMahon M; Muthusamy V; Bosenberg MW. 2010. Characterization of melanoma cells capable of propagating tumors from a single cell. Cancer Res 70(1):388-97. [PubMed: 20048081] [MGI Ref ID J:155731]
Karreth FA; Tay Y; Perna D; Ala U; Tan SM; Rust AG; Denicola G; Webster KA; Weiss D; Perez-Mancera PA; Krauthammer M; Halaban R; Provero P; Adams DJ; Tuveson DA; Pandolfi PP. 2011. In Vivo Identification of Tumor- Suppressive PTEN ceRNAs in an Oncogenic BRAF-Induced Mouse Model of Melanoma. Cell 147(2):382-95. [PubMed: 22000016] [MGI Ref ID J:177503]
Landrette SF; Cornett JC; Ni TK; Bosenberg MW; Xu T. 2011. piggyBac transposon somatic mutagenesis with an activated reporter and tracker (PB-SMART) for genetic screens in mice. PLoS One 6(10):e26650. [PubMed: 22039523] [MGI Ref ID J:179725]
Levy C; Khaled M; Robinson KC; Veguilla RA; Chen PH; Yokoyama S; Makino E; Lu J; Larue L; Beermann F; Chin L; Bosenberg M; Song JS; Fisher DE. 2010. Lineage-specific transcriptional regulation of DICER by MITF in melanocytes. Cell 141(6):994-1005. [PubMed: 20550935] [MGI Ref ID J:167944]
Liu W; Monahan KB; Pfefferle AD; Shimamura T; Sorrentino J; Chan KT; Roadcap DW; Ollila DW; Thomas NE; Castrillon DH; Miller CR; Perou CM; Wong KK; Bear JE; Sharpless NE. 2012. LKB1/STK11 inactivation leads to expansion of a prometastatic tumor subpopulation in melanoma. Cancer Cell 21(6):751-64. [PubMed: 22698401] [MGI Ref ID J:189285]
Mitra D; Luo X; Morgan A; Wang J; Hoang MP; Lo J; Guerrero CR; Lennerz JK; Mihm MC; Wargo JA; Robinson KC; Devi SP; Vanover JC; D'Orazio JA; McMahon M; Bosenberg MW; Haigis KM; Haber DA; Wang Y; Fisher DE. 2012. An ultraviolet-radiation-independent pathway to melanoma carcinogenesis in the red hair/fair skin background. Nature 491(7424):449-53. [PubMed: 23123854] [MGI Ref ID J:189208]
Monahan KB; Rozenberg GI; Krishnamurthy J; Johnson SM; Liu W; Bradford MK; Horner J; Depinho RA; Sharpless NE. 2010. Somatic p16(INK4a) loss accelerates melanomagenesis. Oncogene :. [PubMed: 20697345] [MGI Ref ID J:164588]
Rabbani P; Takeo M; Chou W; Myung P; Bosenberg M; Chin L; Taketo MM; Ito M. 2011. Coordinated activation of wnt in epithelial and melanocyte stem cells initiates pigmented hair regeneration. Cell 145(6):941-55. [PubMed: 21663796] [MGI Ref ID J:173080]
Shah M; Bhoumik A; Goel V; Dewing A; Breitwieser W; Kluger H; Krajewski S; Krajewska M; Dehart J; Lau E; Kallenberg DM; Jeong H; Eroshkin A; Bennett DC; Chin L; Bosenberg M; Jones N; Ronai ZA. 2010. A Role for ATF2 in Regulating MITF and Melanoma Development. PLoS Genet 6(12):e1001258. [PubMed: 21203491] [MGI Ref ID J:167512]
Health & husbandry
Health & Colony Maintenance Information
Animal Health Reports
Room Number FGB29
Colony Maintenance
Breeding & Husbandry When maintaining a live colony, these mice can be bred as hemizygous for the Tg(Tyr-cre/ERT2)13Bos transgene, heterozygous for the Braftm1Mmcm allele and heterozygous for the floxed Ptentm1Hwu allele. 25% of mice that are hemizygous for the Tg(Tyr-cre/ERT2)13Bos transgene, heterozygous for the Braftm1Mmcm allele and homozygous for the floxed Ptentm1Hwu allele will develop melanomas with an onset of 2 to 12 months of age. Mating System
Pricing and Purchasing
Pricing, Supply Level & Notes, Controls
| Pricing for USA, Canada and Mexico shipping destinations |
|
Live Mice
Price per mouse (US dollars $) Gender Genotypes Provided Individual Mouse $232.00 Female or Male Heterozygous for Braftm1Mmcm, Heterozygous for Ptentm1Hwu, Hemizygous for Tg(Tyr-cre/ERT2)13Bos $232.00 Female or Male Heterozygous for Braftm1Mmcm, Heterozygous for Ptentm1Hwu, Noncarrier Individual Mouse $232.00 Female or Male Heterozygous for Braftm1Mmcm, Homozygous for Ptentm1Hwu, Hemizygous for Tg(Tyr-cre/ERT2)13Bos $232.00 Female or Male Homozygous for Braftm1Mmcm, Homozygous for Ptentm1Hwu, Hemizygous for Tg(Tyr-cre/ERT2)13Bos
Price per Pair (US dollars $) Pair Genotype $464.00 Heterozygous for Braftm1Mmcm, Heterozygous for Ptentm1Hwu, Hemizygous for Tg(Tyr-cre/ERT2)13Bos x Heterozygous for Braftm1Mmcm, Heterozygous for Ptentm1Hwu, Noncarrier $464.00 Heterozygous for Braftm1Mmcm, Heterozygous for Ptentm1Hwu, Noncarrier x Heterozygous for Braftm1Mmcm, Heterozygous for Ptentm1Hwu, Hemizygous for Tg(Tyr-cre/ERT2)13Bos Standard Supply
Repository-Live. Repository-Live represents an exclusive set of over 1500 unique mouse models maintained at The Jackson Laboratory to support a vast array of research areas. The breeding colonies for Repository Strains provide mice for both large and small orders and fluctuate in size depending on current demand for each strain. Repository-live orders are treated as custom orders. Within 2 business days, we respond to each availability inquiry or order with various delivery options. Repository Strains typically are delivered at 4 to 8 weeks of age and will not exceed 12 weeks of age on the day of shipping.
| Pricing for International shipping destinations |
|
Live Mice
Price per mouse (US dollars $) Gender Genotypes Provided Individual Mouse $301.60 Female or Male Heterozygous for Braftm1Mmcm, Heterozygous for Ptentm1Hwu, Hemizygous for Tg(Tyr-cre/ERT2)13Bos $301.60 Female or Male Heterozygous for Braftm1Mmcm, Heterozygous for Ptentm1Hwu, Noncarrier Individual Mouse $301.60 Female or Male Heterozygous for Braftm1Mmcm, Homozygous for Ptentm1Hwu, Hemizygous for Tg(Tyr-cre/ERT2)13Bos $301.60 Female or Male Homozygous for Braftm1Mmcm, Homozygous for Ptentm1Hwu, Hemizygous for Tg(Tyr-cre/ERT2)13Bos
Price per Pair (US dollars $) Pair Genotype $603.20 Heterozygous for Braftm1Mmcm, Heterozygous for Ptentm1Hwu, Hemizygous for Tg(Tyr-cre/ERT2)13Bos x Heterozygous for Braftm1Mmcm, Heterozygous for Ptentm1Hwu, Noncarrier $603.20 Heterozygous for Braftm1Mmcm, Heterozygous for Ptentm1Hwu, Noncarrier x Heterozygous for Braftm1Mmcm, Heterozygous for Ptentm1Hwu, Hemizygous for Tg(Tyr-cre/ERT2)13Bos Standard Supply
Repository-Live. Repository-Live represents an exclusive set of over 1500 unique mouse models maintained at The Jackson Laboratory to support a vast array of research areas. The breeding colonies for Repository Strains provide mice for both large and small orders and fluctuate in size depending on current demand for each strain. Repository-live orders are treated as custom orders. Within 2 business days, we respond to each availability inquiry or order with various delivery options. Repository Strains typically are delivered at 4 to 8 weeks of age and will not exceed 12 weeks of age on the day of shipping.
|
|
|
Standard Supply
Repository-Live. Repository-Live represents an exclusive set of over 1500 unique mouse models maintained at The Jackson Laboratory to support a vast array of research areas. The breeding colonies for Repository Strains provide mice for both large and small orders and fluctuate in size depending on current demand for each strain. Repository-live orders are treated as custom orders. Within 2 business days, we respond to each availability inquiry or order with various delivery options. Repository Strains typically are delivered at 4 to 8 weeks of age and will not exceed 12 weeks of age on the day of shipping.
Control Information
| Control | ||
|---|---|---|
| 000664 C57BL/6J | ||
| Considerations for Choosing Controls | ||
| Control Pricing Information for Genetically Engineered Mutant Strains. | ||
Payment Terms and Conditions
Terms are granted by individual review and stated on the customer invoice(s) and account statement. These transactions are payable in U.S. currency within the granted terms. Payment for services, products, shipping containers, and shipping costs that are rendered are expected within the payment terms indicated on the invoice or stated by contract. Invoices and account balances in arrears of stated terms may result in The Jackson Laboratory pursuing collection activities including but not limited to outside agencies and court filings.
See Terms of Use tab for General Terms and Conditions
The Jackson Laboratory's Genotype Promise
The Jackson Laboratory has rigorous genetic quality control and mutant gene genotyping programs to ensure the genetic background of JAX® Mice strains as well as the genotypes of strains with identified molecular mutations. JAX® Mice strains are only made available to researchers after meeting our standards. However, the phenotype of each strain may not be fully characterized and/or captured in the strain data sheets. Therefore, we cannot guarantee a strain's phenotype will meet all expectations. To ensure that JAX® Mice will meet the needs of individual research projects or when requesting a strain that is new to your research, we suggest ordering and performing tests on a small number of mice to determine suitability for your particular project.Ordering Information
JAX® Mice
Surgical and Preconditioning Services
JAX® Services
Customer Services and Support
Tel: 1-800-422-6423 or 1-207-288-5845
Fax: 1-207-288-6150
Technical Support Email Form
Terms of Use
Terms of Use
General Terms and Conditions
For Licensing and Use Restrictions view the link(s) below:
- Mice are subject to US Patent 6040430.
- Notice to customers in Canada.
- Use of MICE by companies or for-profit entities requires a license prior to shipping.
- Use of MICE by companies or for-profit entities requires a license prior to shipping.
- Use of MICE by companies or for-profit entities requires a license prior to shipping.
Contact information
General inquiries regarding Terms of UseContracts Administration
| phone: | 207-288-6470 |
| fax: | 207-288-6655 |
JAX® Mice, Products & Services Conditions of Use
"MICE" means mouse strains, their progeny derived by inbreeding or crossbreeding, unmodified derivatives from mouse strains or their progeny supplied by The Jackson Laboratory ("JACKSON"). "PRODUCTS" means biological materials supplied by JACKSON, and their derivatives. "RECIPIENT" means each recipient of MICE, PRODUCTS, or services provided by JACKSON including each institution, its employees and other researchers under its control. MICE or PRODUCTS shall not be: (i) used for any purpose other than the internal research, (ii) sold or otherwise provided to any third party for any use, or (iii) provided to any agent or other third party to provide breeding or other services. Acceptance of MICE or PRODUCTS from JACKSON shall be deemed as agreement by RECIPIENT to these conditions, and departure from these conditions requires JACKSON's prior written authorization.No Warranty
MICE, PRODUCTS AND SERVICES ARE PROVIDED “AS IS”. JACKSON EXTENDS NO WARRANTIES OF ANY KIND, EITHER EXPRESS, IMPLIED, OR STATUTORY, WITH RESPECT TO MICE, PRODUCTS OR SERVICES, INCLUDING ANY IMPLIED WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, OR ANY WARRANTY OF NON-INFRINGEMENT OF ANY PATENT, TRADEMARK, OR OTHER INTELLECTUAL PROPERTY RIGHTS.
In case of dissatisfaction for a valid reason and claimed in writing by a purchaser within ninety (90) days of receipt of mice, products or services, JACKSON will, at its option, provide credit or replacement for the mice or product received or the services provided.
No Liability
In no event shall JACKSON, its trustees, directors, officers, employees, and affiliates be liable for any causes of action or damages, including any direct, indirect, special, or consequential damages, arising out of the provision of MICE, PRODUCTS or services, including economic damage or injury to property and lost profits, and including any damage arising from acts or negligence on the part of JACKSON, its agents or employees. Unless prohibited by law, in purchasing or receiving MICE, PRODUCTS or services from JACKSON, purchaser or recipient, or any party claiming by or through them, expressly releases and discharges JACKSON from all such causes of action or damages, and further agrees to defend and indemnify JACKSON from any costs or damages arising out of any third party claims.
MICE and PRODUCTS are to be used in a safe manner and in accordance with all applicable governmental rules and regulations.
The foregoing represents the General Terms and Conditions applicable to JACKSON’s MICE, PRODUCTS or services. In addition, special terms and conditions of sale of certain MICE, PRODUCTS or services may be set forth separately in JACKSON web pages, catalogs, price lists, contracts, and/or other documents, and these special terms and conditions shall also govern the sale of these MICE, PRODUCTS and services by JACKSON, and by its licensees and distributors.
Acceptance of delivery of MICE, PRODUCTS or services shall be deemed agreement to these terms and conditions. No purchase order or other document transmitted by purchaser or recipient that may modify the terms and conditions hereof, shall be in any way binding on JACKSON, and instead the terms and conditions set forth herein, including any special terms and conditions set forth separately, shall govern the sale of MICE, PRODUCTS or services by JACKSON.